{"id":"W4283579364","doi":"10.1136/annrheumdis-2022-eular.2534","title":"OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Foundation for Research in Rheumatology; Universitair Medisch Centrum Groningen; Eli Lilly and Company","keywords":"Medicine; BASDAI; Axial spondyloarthritis; Internal medicine; Placebo; Population; Ankylosing spondylitis; Randomized controlled trial; Clinical endpoint; Physical therapy; Gastroenterology; Surgery; Arthritis; Pathology; Psoriatic arthritis; Sacroiliitis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001610533,0.002040077,0.004008878,0.000400449,0.0005168412,0.001537135,0.000953986,0.002280765,0.006668941],"category_scores_gemma":[0.001733823,0.0007212125,0.002596612,0.0004852449,0.001363187,0.001510444,0.0003689697,0.004249394,0.00124729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007086827,"about_ca_system_score_gemma":0.00112216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007143452,"about_ca_topic_score_gemma":0.001731838,"domain_scores_codex":[0.999466,0.0002281301,0.00003524035,0.00009774405,0.00004965303,0.000123174],"domain_scores_gemma":[0.9992099,0.000261351,0.0001695171,0.0000567523,0.00006195116,0.0002405296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9773685,0.003056406,0.0003818382,0.001104997,0.001136671,0.00005245399,0.00003889816,0.0002652023,0.001738511,0.000115071,0.001058574,0.01368294],"study_design_scores_gemma":[0.9661347,0.03085615,0.001193798,0.00004906279,0.0005955146,0.00004413624,0.00001911887,0.000294086,0.0002646059,0.0001057917,0.0004252372,0.00001776808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758697,0.0130798,0.0009067967,0.0009725096,0.0008188062,0.003038055,0.00160899,0.0002499482,0.0034554],"genre_scores_gemma":[0.9852462,0.005039262,0.0009890603,0.001371368,0.0004540949,0.002478904,0.001607876,0.0000368437,0.002776393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006668941,"threshold_uncertainty_score":0.0223099,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02188170937855519,"score_gpt":0.299956462843637,"score_spread":0.2780747534650818,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}